Impact of novel N-aryl substituted piperamide on NF-kappa B translocation as a potent anti-neuroinflammatory agent.

NF-kB translocation is the key point in the upstream neuroinflammatory pathways. It plays an import role in the pro-inflammatory chemokine, cytokine, and various enzyme expressions, consequently leading to the inflammatory response of the innate immune system. The NF-kB complex consists of structural homolog subunits, including c-Rel, RelB, p52, p65, and p50. Among the p65 subunit has a vital function of NF-kB translocation and DNA binding. NF-kB translocation may occur due to acetylation and phosphorylation LYS 310 and SER311 amino acids in chain A of the p65 subunit in response to IKK-α/β activity. Therefore, there are two ways to inhibit the NF-kB translocation, either directly blocking the active sites of IKK-α/β enzymes or protecting the LYS 310 and SER311 of p65 subunit from acetylation and phosphorylation. NF-kB translocation inhibitors can maintain the NF-kB complex in the inactive form inside the cytosol. In this study, we have designed and developed an NF-kB translocation inhibitor, D4. We have performed various in silico, in vitro and in situ studies on the anti-neuroinflammatory function of D4. It showed the ability to inhibit IKK-α/β in both genome and proteome levels and protect LYS310 of the p65 subunit of NF-kB from the acetylation process. Therefore, we can suggest D4 as the promising anti-neuroinflammatory agent with a function on the upstream process of inflammatory pathways.

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The author(s) declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.